Purpose To compare the effectiveness of metastatic tumor response evaluation with computed tomography using computer-assisted versus manual methods. Materials and Methods In this institutional review board-approved, Health Insurance Portability and Accountability Act-compliant retrospective study, 11 readers from 10 different institutions independently categorized tumor response according to three different therapeutic response criteria by using paired baseline and initial post-therapy computed tomography studies from 20 randomly selected patients with metastatic renal cell carcinoma who were treated with sunitinib as part of a completed phase III multiinstitutional study. Images were evaluated with a manual tumor response evaluation method (standard of care) and with computer-assisted response evaluation (CARE) that included stepwise guidance, interactive error identification and correction methods, automated tumor metric extraction, calculations, response categorization, and data and image archiving. A crossover design, patient randomization, and 2-week washout period were used to reduce recall bias. Comparative effectiveness metrics included error rate and mean patient evaluation time.
INTRODUCTION
In clinical trials and clinical practice, objective tumor response as evaluated on computed tomography (CT) images defines critical end points in patients with metastatic disease who are treated with systemic agents. Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1) is based on tumor length measurements and is the most commonly used criteria with which to longitudinally assess metastatic tumor response for a wide variety of solid malignancies. 1, 2 In the era of targeted therapy, metastatic tumor shrinkage has become less common or is delayed, which limits the utility of RECIST version 1.1. [3] [4] [5] [6] [7] Many targeted agents are classified as antiangiogenic and cause tumor devascularization, which leads to changes in tumor size, attenuation, and morphology on CT images. 8, 9 Choi criteria, which uses the percent change in tumor length and attenuation to derive objective response, was initially successful in predicting tumor response and survival in metastatic GI stromal tumors; however, less consistent results were observed when Choi criteria were applied to metastatic renal cell carcinoma (RCC) that was treated with antiangiogenic targeted agents. 8, 9 MASS (Morphology, Attenuation, Size, and Structure) criteria, which accounts for objective changes in tumor length and attenuation and subjective development of tumor necrosis, was subsequently developed and found to be predictive of progression-free survival in patients with metastatic RCC who were treated with antiangiogenic targeted agents.
Computer-assisted detection, picture archiving and communications systems, voice recognition systems, and electronic medical records have been designed to provide guidance, automate tasks, reduce errors, and improve efficiency and documentation in diagnostic imaging. 10, 11 Despite advances in tumor segmentation methods and data management, the current standard of care for assessing metastatic tumor response is to manually apply tumor response criteria to derive objective response and manually document the findings. [12] [13] [14] [15] These manual methods are prone to human errors in target lesion selection, target lesion measurement, data transfer, data calculations, response categorization, and archiving of data and annotated images. [16] [17] [18] [19] Furthermore, these manual methods are potentially inefficient and become particularly complex when evaluating images by multiple imaging criteria, which is becoming more common in oncologic clinical trials. 20, 21 A computer-assisted response evaluation (CARE) system has been developed to guide readers through and to automate many of the steps in tumor response assessment with the goal of reducing errors and improving efficiency and documentation. 22 In this study, we compared the effectiveness of metastatic tumor response evaluation in patients with RCC using standard of care versus a CARE method.
MATERIALS AND METHODS

Study Design
Informed consent was waived in this institutional review board-approved, Health Insurance Portability and Accountability Act-compliant, retrospective, multi-institutional comparative-effectiveness observational study.
Participants
An existing imaging data set from a multinational, multi-institutional, prospective phase III trial of adult patients with metastatic clear-cell RCC who were treated with sunitinib or interferon alfa was used. 23 Three hundred seventy-five participants were included in the sunitinib arm. CT images from this study were prospectively archived for central independent review. Patients with unavailable baseline imaging or initial posttherapy imaging (n = 61) and those with nondigitized images (n = 39) were excluded, which left 275 participants available for analysis. For our study, images from 20 of 275 participants were randomly selected for additional evaluation. A power analysis for 11 readers with a cluster correlation of 50% and expected patient-level error percentage of 20% for standard of care and 2% for CARE yielded greater than 90% power to detect differences between the two methods.
Image Acquisition
Baseline CT (CT0) and initial follow-up CT (CT1) imaging of the chest, abdomen, and pelvis were performed per routine institutional acquisition parameters with slice thickness at < 5 mm and administration of intravenous iodinated contrast unless contraindicated. Other CT acquisition and contrast material injection parameters were not specified, although CT manufacturer, number of detector rows, and tube voltage were obtained from images (Table 1) . Images were deidentified with a unique coded identifier that was applied to each CT examination.
Readers
Eleven readers from 10 institutions participated in this study. Readers had a median of 5 years of post-training clinical experience (range, 2 to 23 years) and were practicing American Board of Radiology-certified academic radiologists with fellowship training in body imaging. Readers were provided with a written overview of RECIST version 1.1 and Choi and MASS criteria as well as relevant literature concerning the various tumor response criteria they were asked to review.
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Standard-of-Care Method Readers were provided remote access to a standard image viewer (Philips iSite Enterprise, version 3.6.150.0 test environment; Philips, Andover, MA). Readers used coded identification numbers to locate and view CT0 and CT1 images. A Webbased Qualtrics survey platform (Provo, UT) was used to record data on target lesions and was designed to mimic the use of electronic data capture devices that are used in modern oncologic clinical trials. Target lesion data entered by each reader included the type of target lesion (primary tumor, metastasis, or lymph node), target lesion length (centimeters), and mean attenuation (Hounsfield units), calculated percent change in length and mean attenuation, presence or absence of marked decreased attenuation or marked central necrosis per MASS criteria, nontarget lesion response, and objective response per RECIST version 1.1 and Choi and MASS criteria. All readers reviewed a 30-minute instructional video that detailed the approach to the standard-of-care method, use of the Qualtrics survey to record results, and a requirement to archive all images that were annotated during review. Qualtrics was used to time the tumor response assessment for each patient interpretation, from the loading of the survey to export of the data.
CARE Method
A custom image-viewing and semiautomated advanced postprocessing software platform (eMASS) was developed by A.D.S. and iteratively improved upon in collaboration with software engineers from ImageIQ. 22 In brief, eMASS software was designed to facilitate CARE of target lesions on baseline and initial post-therapy imaging studies by providing stepwise guidance of the required measurements and observations, interactive error identification and correction methods, and automated tumor metric extraction, calculations, response categorization, and data/image archiving. The software identifies common errors in tumor response assessment and implements corrective measures as detailed in Table 2 . [16] [17] [18] [19] Efficiency is improved via automation of multiple steps, including the simultaneous extraction of bidimensional tumor length and mean attenuation from a manual tumor segmentation process in which free-form regions of interest are drawn around the periphery of target lesions by the reviewer. The software automatically archives all data, annotates images, and instantly generates a summary output display for the reader to review (Fig 1) .
All readers reviewed a 30-minute instructional video that detailed the use of the CARE method. A password-restricted encrypted data sharing platform (Dropbox, San Francisco, CA) was used to share eMASS software (version 1.0.24; eMASS LLC, Birmingham, AL) and deidentified images. Readers used their local personal computer running Windows 7 or higher (Microsoft, Redmond, WA) to download the stand-alone software package. The software automatically timed the tumor response assessment for each patient interpretation from the time of image loading until data export. Exported data are automatically stored in a comma-separated value format database. Exported images are automatically stored in Digital Imaging and Communications in Medicine and Portable Network Graphics formats in the main directory of the software.
Reading Sessions
All patients were evaluated once by using the standard-of-care method and twice by using the CARE method, with differences in how target lesions were identified. A crossover design, patient random assignment, and 2-week washout period were used to reduce recall bias (Appendix, online only). In brief, a total of 11 readers participated. Two reader pools (1 and 2) and three reading sessions (A, B, and C) were used. For reading sessions A and B, readers were provided with CT0 and CT1 images and independently picked their own target lesions as they evaluated images. Reading session C used the CARE method only, was designed to eliminate interobserver variability as a result of target lesion selection, and used a set 
Selection of more than five total target lesions
Assign all target lesions a number and prohibit the selection of more than five target lesions.
Selection of more than two target lesions per organ system
Require assignment of all target lesions to an organ system by using a dropdown list, provide user with a warning when selection of more than two target lesions per organ system is made, and prevent additional analysis until error is corrected.
Selection of a metastasis measuring , 1.0 cm in long axis
Require labeling of all target lesions as primary mass, metastasis, or lymph node. Notify reader of an error if primary mass or metastasis measures , 1.0 cm in long axis or if lymph node measures , 1.5 cm in short axis, and prevent additional analysis until error is corrected.
Selection of a lymph node measuring ,
cm in short axis
Error in target lesion measurement
Metastasis measured in short axis
Eliminate manual data transfer. The user places a free-form ROI around the peripheral margin of the tumor on the axial image where the target lesion is the largest (per RECIST version 1.1 guidelines). The long axis length is automatically derived and archived in a database for all target lesions labeled as a primary mass or metastasis. The short axis length is automatically derived and archived in a database for all target lesions labeled as lymph nodes.
Lymph node measured in long axis
Error in data transfer
. 0.5 cm in length between annotated image and database Eliminate manual data transfer by automatically extracting and archiving all tumor metric data. arrangement of target lesion images that were provided to all readers.
For reading session A, reader pool 1 evaluated participants 1 to 10 by using the standard-of-care method, followed by participants 11 to 20 by using the CARE method. Reader pool 2 evaluated participants 11 to 20 by using the standard-of-care method, followed by participants 1 to 10 by using the CARE method.
To reduce recall bias, readers waited at least 14 days before beginning session B. For reading session B, reader pool 1 evaluated participants 1 to 10 in a randomized order by using the CARE method, followed by participants 11 to 20 in a randomized order by using the standard-of-care method. Reader pool 2 evaluated participants 11 to 20 in a randomized order by using the CARE method, followed by participants 1 to 10 in a randomized order by using the standard-of-care method (Appendix Fig A1, online only) .
Reading session C was designed to eliminate interobserver variability as a result of target lesion selection. Target lesions were identified by A.D.S., and single Digital Imaging and Communications in Medicine format images with each target lesion from CT0 and CT1 were provided to readers. All readers used an imaging atlas-digital slides that contained pictures of each target lesion with an arrow pointing to the target-and evaluated participants 1 to 20 by using the CARE method. For the purposes of this article, CARE1 indicates that the readers picked their own target lesions, and CARE2 indicates that the target lesions were preselected for the readers.
Tumor Response Error Rate and Type Analysis
Two imaging research fellows-E.F. and R.S.-independently used the output data from the Qualtrics platform and the output file from the CARE method, along with the archived annotated images, to manually identify and record the presence or absence of all common tumor response error types identified in Table 2 . Only a single error event per patient was recorded for each error type, even if multiple errors of the same type occurred in the same patient. A third reviewer-B.C.A., a reader from the study-evaluated all potential errors that were identified by E.F. and R.S. In the case of any discrepancy between the three reviewers, a panel that consisted of five readers from the study evaluated the potential errors by consensus.
Post-study Survey
A post-study Qualtrics survey that was unrelated to the data capture mechanism and designed to assess reader opinion about the CARE method was completed by all readers (N = 11) before an analysis of the study data and results. 
Statistical Analysis
Patient, imaging, and measurement characteristics were summarized as median and interquartile range for continuous variables and count (percentage) for categorical variables for both the 275 patients who satisfied the inclusion criteria and the subset of 20 patients used in primary results.
Side-by-side boxplots were constructed to compare interpretation time between standard-of-care and CARE1 methods. Scatter plots were constructed to visualize the distributions of the percent change in tumor length and mean attenuation in each patient by using the standard-of-care, CARE1, and CARE2 methods.
Average percent of errors per patient was calculated by using the marginal effect from a multilevel 
RESULTS
Patient, Tumor, and Imaging Characteristics
The study cohort (n = 20) was randomly selected from the full cohort (N = 275) and had similar baseline characteristics (Table 1) .
Tumor Response Error Rate and Type
The standard-of-care method was associated with errors types in all categories, including target lesion selection, target lesion measurement, data transfer, application of MASS criteria, tumor metric calculations, objective response categorization, and annotated image archiving (Table 3) . The most common errors were related to data transfer and calculation.
The standard-of-care method, on average, was associated with one or more errors in 30.5% (6.1 of Table A1 ). The median error rate for 11 readers who interpreted 20 cases using the standard-ofcare method was 25% (range, 15% to 55%). In patients with errors, the median number of error types was 1 (range, 1 to 3). When considering total errors per response criteria using the standard-ofcare method, errors were more common when applying Choi criteria (24.5% 
Interpretation Time
Mean patient interpretation time was twice as fast when using the CARE compared with the standard-of-care method: 6.4 minutes (95% CI, 6.11 to 6.66) v 13.1 minutes (95% CI, 12.5 to 13.7), respectively (P , .001; Appendix Fig A2, online only).
Interobserver Agreement
Interobserver agreement results are summarized in Table 4 . There was very good interobserver agreement for measuring length and mean attenuation when readers used the CARE method to evaluate preselected target lesions (CARE2 range of ICC, 0.95 to 0.98), which resulted in a higher level of agreement than when readers chose their own target lesions (standard-of-care range of ICC, 0.59 to 0.89; CARE1 range of ICC, 0.69 to 0.88). Similarly, improved interobserver agreement for measuring the percent change in length was observed when readers used the CARE method to evaluate preselected target lesions (CARE2 ICC, 0.89), which resulted in a higher level of agreement than when readers chose their own target lesions (standard-of-care ICC, 0.79; CARE1 ICC, 0.59); however, when using either readerselected or preselected target lesions, there was poor agreement for the percent change in mean attenuation (range of ICC, 0.00 to 0.06), which is used in Choi criteria. Distributions of the percent change in tumor length and mean attenuation for each patient according to tumor response evaluation method are depicted graphically in Fig 2. 
Post-study Survey
The post-study survey indicated that 100% of readers (11 of 11) strongly preferred the CARE method and found CARE to be much easier to use than the Name: Blinded MRN: Blinded
Target 1 Lung
C T 0 Date Blinded
C T 1 Date Blinded
Target 2 Lung
Target 3 Mediastinal LN
Target 4
Liver standard-of-care method. Most readers (73%; eight of 11) indicated that CARE would improve overall productivity in the clinical setting, with 18% (two of 11) undecided and 9% (one of 11) indicating that productivity would not be improved. Additional survey results are provided in the Appendix.
DISCUSSION
The current standard-of-care for assessing metastatic tumor response is to manually apply tumor response criteria to derive the objective response and manually document the results. In our study, the standard-of-care method was associated with a high error rate, despite the use of expert readers and training before reading sessions. Similar findings have been reported by using RECIST version 1.1 in clinical practice, but have not been confirmed in a multi-institutional study. 17 Past efforts to reduce reader errors and interobserver variability in tumor response assessment have included reader educational training and the use of central independent image review in oncologic clinical trials, which have mildly reduced errors and improved interobserver variability. 17, [25] [26] [27] In our study, the use of the CARE method with step-wise guidance and interactive error identification and correction methods eliminated reader errors and achieved good to very good interobserver agreement. This is a clinically important finding, as errors in tumor response evaluation may adversely impact treatment decisions. CARE was used to automate tumor metric extraction, calculations, response categorization, and data and image archiving, which resulted in markedly improved efficiency as the mean interpretation time was cut in half compared with the standard-of-care method.
We observed high inter-reader agreement for measuring multiple tumor metrics by using the CARE method, despite the use of 11 readers from 10 different institutions with varying experience and practice patterns with less than 1 hour of training with the CARE method. Two observations are noteworthy. First, interobserver agreement using either the standard-of-care or CARE methods for measuring mean attenuation was good, but was dismal for percent change in mean tumor attenuation, even when all readers measured the same preselected target lesions. This implies that the mathematical conversion to percent change in mean attenuation is responsible for the poor interobserver agreement, which is likely related to the fact that zero mean attenuation is an arbitrarynot absolute-definition and is not comparable to a length measurement of zero, which is an absolute value that indicates that no tumor is present. These findings suggest that the percent change in mean attenuation may not be reproducible in Choi criteria and modified Choi criteria. Second, interobserver agreement for measuring length with the CARE method was higher when target lesions were preselected for readers than when readers selected their own target lesions, which indicated that target lesion selection is a major contributor to interobserver variability.
This study had several limitations. First, the study was retrospective in design, although CT images were a representative sample from a landmark multinational, multi-institutional, phase III prospective study and the standard-of-care tumor response evaluation process was similar to methods that are used in prospective multi-institutional studies. Second, the high per-patient error rates in our study likely underestimate true error rates as readers only evaluated two imaging time points and did not perform longitudinal tumor assessments that are used in clinical trials and clinical practice and only one error type per patient was counted, despite the possibility of compounded errors-for example, a target lesion selection error that leads to measurement, calculation, and response categorization errors at the current time point or later time points. Third, the same set of patient images was evaluated twice by readers so that a direct comparison of two tumor response assessment methods could be made, potentially leading to recall bias. Efforts to reduce recall bias included the crossover study design, patient randomization and deidentification, and a 2-week washout period between reading sessions. Fourth, the study was not designed or powered to assess longitudinal differences in objective tumor response reclassification or changes in clinical management associated with use of the CARE method. Fifth, our study focused only on tumor assessments using CT images; however, the basic rule-setting structure is amenable to other imaging modalities.
In conclusion, the CARE method significantly reduces errors and time of evaluation while maintaining high interobserver agreement, which indicates better overall effectiveness than manual tumor response evaluation methods that are the current standard of care. As metastatic tumor response evaluation defines critical end points in oncologic patient care, methods that reduce errors, reduce time of evaluation, and improve documentation while maintaining high interobserver agreement could lead to needed advancements in clinical trials and clinical care.
APPENDIX Reading Sessions
All patients were evaluated once by using the standard-of-care method and twice by using the computer-assisted response evaluation (CARE) method, with differences in how target lesions were identified. A crossover design, patient random assignment, and 2-week washout period were used to reduce recall bias. In brief, a total of 11 readers participated. Two reader pools (1 and 2) and three reading sessions (A, B, and C) were used. For reading sessions A and B, readers were provided with images from baseline computed tomography exam and initial follow-up computed tomography exam, and readers independently picked their own target lesions as they evaluated the images. Reading session C used the CARE method only, was designed to eliminate interobserver variability as a result of target lesion selection, and used a set arrangement of target lesion images that were provided to all readers.
For reading session A, reader pool 1 evaluated participants 1 to 10 by using the standard-of-care method followed by participants 11 to 20 by using the CARE method. Reader pool 2 evaluated participants 11 to 20 by using the standard-of-care method followed by participants 1 to 10 by using the CARE method.
To reduce recall bias, readers waited at least 14 days before beginning session B. For reading session B, reader pool 1 evaluated participants 1 to 10 in a randomized order by using the CARE method followed by participants 11 to 20 in a randomized order by using the standard-of-care method. Reader pool 2 evaluated participants 11 to 20 in a randomized order by using the CARE method followed by participants 1 to 10 in a randomized order by using the standard-of-care method (Fig. A1 ).
Reading session C was designed to eliminate interobserver variability as a result of target lesion selection. Target lesions were identified by A.D.S. and single Digital Imaging and Communications in Medicine format images with each target lesion from baseline computed tomography exam and initial follow-up computed tomography exam were provided to readers. All readers used an imaging atlas-digital slides that contained pictures of each target lesion with an arrow pointing to the target-and evaluated participants 1 to 20 by using the CARE method. For the purposes of this article, CARE1 indicates that the readers picked their own target lesions, and CARE2 indicates that the target lesions were preselected for the readers.
Post-study Survey
The post-study survey indicated that 100% of readers (11 of 11) strongly preferred the CARE method and found CARE to be much easier to use than the standard-of-care method. Most readers (73%; eight of 11) indicated that CARE would improve overall productivity in the clinical setting, with 18% (two of 11) undecided and 9% (one of 11) indicating that productivity would not be improved. Most readers (82%; nine of 11) indicated that CARE would improve accuracy compared with the standard-of-care method, with 9% (one of 11) undecided, and 9% (one of 11) indicating that CARE would not improve accuracy. Most readers (82%; nine of 11) indicated that they would be very likely to use CARE in the future, with 9% (one of 11) indicating that they were somewhat likely and 9% (one of 11) undecided. 
